ADMA Biologics ADMA Accrued Rebates Current
Accrued Rebates Current at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept adma:AccruedRebatesCurrent.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's accrued rebates current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's accrued rebates current?
- ADMA Biologics (ADMA) reported accrued rebates current of $7.16M in Q1 2026.
- How has ADMA Biologics's accrued rebates current changed year-over-year?
- ADMA Biologics's accrued rebates current increased by 47.7% year-over-year, from $4.85M to $7.16M.
- What is the long-term trend for ADMA Biologics's accrued rebates current?
- Over 5 years (2020 to 2025), ADMA Biologics's accrued rebates current has grown at a 17.2% compound annual growth rate (CAGR), from $2.6M to $5.76M.
- What does accrued rebates current mean?
- This represents the estimated liability for rebates owed to customers or distributors, typically related to sales volume or contractual pricing agreements. It is a critical accrual that directly impacts net revenue recognition and reflects the company's commercial incentive structure. High or increasing levels may indicate aggressive sales strategies or changing competitive pricing dynamics.